The top 5 stocks are presented in rankings of companies with high first-quarter progress rates and stocks rated bullish by analysts. Mitsui O.S.K. Lines ranked first with a progress rate of approximately 33%, partly reflecting the impact of the situation in the Middle East, while drug discovery ventures Nxera Pharma and PeptiDream received bullish ratings.
The top 5 companies with the highest first-quarter progress rates were published for companies with fiscal years ending in March. All had first-quarter progress rates of at least 25%: Mitsui O.S.K. Lines at approximately 32.8%, Astellas Pharma at 28.9%, TDK at 28.7%, Unitika at 28.7% and Workman at 28.3%. Minimum investment amounts were also disclosed, at ¥700,000 for Mitsui O.S.K. Lines, ¥240,000 for Astellas Pharma, ¥290,000 for TDK, ¥140,000 for Unitika and ¥600,000 for Workman.
Next, the “ranking of stocks with bullish analyst ratings” was presented, with drug discovery ventures Nxera Pharma and PeptiDream taking first and second place. Analysts’ bullishness toward Nxera Pharma was described as more than 8 times the level implied by the company’s earnings forecast, while PeptiDream recorded a bullishness rating of 215%. Other stocks listed were Sakura Internet, ROHM and ULVAC.